Innoviva (INVA) Capital Expenditures Growth (1y) (2011 - 2025)
Innoviva (INVA) Capital Expenditures Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 143.40% |
| 10 | Innoviva | 1.60 Bn | 998.77 Mn | 75.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 315.19% |
| Sep 30, 2024 | 3.85% |
| Sep 30, 2023 | 687.88% |
| Mar 31, 2023 | 266.67% |
| Dec 31, 2016 | 2,700.00% |
| Dec 31, 2015 | -99.25% |
| Mar 31, 2015 | -99.63% |
| Dec 31, 2014 | -87.54% |
| Jun 30, 2014 | -253.98% |
| Mar 31, 2014 | 118.92% |
| Dec 31, 2013 | 308.81% |
| Sep 30, 2013 | -58.38% |
| Jun 30, 2013 | 4.86% |
| Mar 31, 2013 | -32.91% |
| Dec 31, 2012 | -71.16% |
| Sep 30, 2012 | 1,517.50% |
| Jun 30, 2012 | -52.32% |
| Mar 31, 2012 | -20.13% |
| Dec 31, 2011 | 57.39% |
| Sep 30, 2011 | -126.14% |